Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Glioblastoma × tivozanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 10 Colorectal Neoplasms 4 Breast Neoplasms 3 Solid Tumors 2 Sarcoma 2 Prostatic Neoplasms 2 Neoplasm Metastasis 2 Gastrointestinal Neoplasms 2 Carcinoma, Non-Small-Cell Lung 2 Bile Duct Neoplasms 2 Vulvar Neoplasms 1 Triple Negative Breast Neoplasms 1 Recurrence 1 Ovarian Neoplasms 1 Neuroendocrine Tumors 1 Neoplasms 1 Liver Neoplasms 1 Hereditary Sensory and Autonomic Neuropathies 1 Glioblastoma 1 Gallbladder Neoplasms 1 Fallopian Tube Neoplasms 1 Disease Progression 1 Disease 1 Clear-cell metastatic renal cell carcinoma 1 Cholangiocarcinoma 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Neuroendocrine 1 Advanced Solid Tumors 1 Advanced Adult Hepatocellular Carcinoma 1

Interventions

Temozolomide 373 Radiotherapy 187 Bevacizumab 143 Radiation 73 Magnetic Resonance Spectroscopy 67 Lomustine 45 pembrolizumab 38 Surgical Procedures, Operative 37 Irinotecan 37 Carmustine 37 Nivolumab 27 Carboplatin 25 Specimen Handling 24 Radiosurgery 23 Erlotinib Hydrochloride 23 Radiotherapy, Intensity-Modulated 20 Chemotherapy, Adjuvant 20 Aminolevulinic Acid 19 Cyclophosphamide 18 Drug Therapy 17 sargramostim 16 O(6)-benzylguanine 14 Radiotherapy, Conformal 13 Granulocyte-Macrophage Colony-Stimulating Factor 13 Blood Specimen Collection 13 Everolimus 12 temsirolimus 11 Vorinostat 11 Sunitinib 11 Imatinib Mesylate 11

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01846871 2019-01-08

Tivozanib for Recurrent Glioblastoma

Massachusetts General Hospital

Phase 2 Completed

10 enrolled 13 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡